DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo

VIVUS, Inc. (NASDAQ: VVUS)



company name or ticker

VIVUS' (VVUS) CEO Seth Fischer on Q2 2014 Results - Earnings Call Transcript

Orexigen Hits Expectations But That Is Not The Big News

Will Emergent BioSolutions (EBS) Earnings Disappoint in Q2? - Analyst Blog

Will Horizon Pharma (HZNP) Earnings Miss Estimates in Q2? - Analyst Blog

Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog

Possible Delay In Orexigen Approval Process In Europe

The Implications of Obesity as a Disability in Europe

Despite rising obesity in Europe, the EU has yet to approve weight loss drugs from Arena (ARNA), Vivus (VVUS), or Orexigen (OREX).

Arena Pharmaceuticals Inc. Still Down After CEO's Sale

It says something about the short-term prospects for Arena Pharmaceuticals. And competitors, Orexigen and VIVUS, for that matter.

Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force - Analyst Blog

3 Crashing Biotechs: Is 1 a Buy?

Here's why Aegerion (AEGR), Vivus (VVUS), and Exelixis (EXEL) are healthcare's worst performers this year.
See More Articles...